GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protalix BioTherapeutics Inc (AMEX:PLX) » Definitions » Days Inventory

Protalix BioTherapeutics (Protalix BioTherapeutics) Days Inventory

: 209.31 (As of Dec. 2023)
View and export this data going back to 2007. Start your Free Trial

Days Inventory is also known as Days Sales of Inventory (DSI). Protalix BioTherapeutics's Average Total Inventories for the three months ended in Dec. 2023 was $20.31 Mil. Protalix BioTherapeutics's Cost of Goods Sold for the three months ended in Dec. 2023 was $8.86 Mil. Hence, Protalix BioTherapeutics's Days Inventory for the three months ended in Dec. 2023 was 209.31.

The historical rank and industry rank for Protalix BioTherapeutics's Days Inventory or its related term are showing as below:

PLX' s Days Inventory Range Over the Past 10 Years
Min: 156.7   Med: 322.79   Max: 3304.7
Current: 309.29

During the past 13 years, Protalix BioTherapeutics's highest Days Inventory was 3304.70. The lowest was 156.70. And the median was 322.79.

PLX's Days Inventory is ranked worse than
67.95% of 649 companies
in the Biotechnology industry
Industry Median: 192.13 vs PLX: 309.29

Protalix BioTherapeutics's Days Inventory declined from Dec. 2022 (597.03) to Dec. 2023 (209.31).

Inventory Turnover measures how fast the company turns over its inventory within a year. Protalix BioTherapeutics's Inventory Turnover for the three months ended in Dec. 2023 was 0.44.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Protalix BioTherapeutics's Inventory-to-Revenue for the three months ended in Dec. 2023 was 1.94.


Protalix BioTherapeutics Days Inventory Historical Data

The historical data trend for Protalix BioTherapeutics's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protalix BioTherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Inventory
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 280.14 356.46 346.45 323.77 284.68

Protalix BioTherapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Days Inventory Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 597.03 548.79 296.38 384.34 209.31

Competitive Comparison

For the Biotechnology subindustry, Protalix BioTherapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protalix BioTherapeutics Days Inventory Distribution

For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's Days Inventory distribution charts can be found below:

* The bar in red indicates where Protalix BioTherapeutics's Days Inventory falls into.



Protalix BioTherapeutics Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Protalix BioTherapeutics's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as

Days Inventory (A: Dec. 2023 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (A: Dec. 2022 ) + Total Inventories (A: Dec. 2023 )) / count ) / Cost of Goods Sold (A: Dec. 2023 )*Days in Period
=( (16.804 + 19.045) / 2 ) / 22.982*365
=17.9245 / 22.982*365
=284.68

Protalix BioTherapeutics's Days Inventory for the quarter that ended in Dec. 2023 is calculated as:

Days Inventory (Q: Dec. 2023 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (Q: Sep. 2023 ) + Total Inventories (Q: Dec. 2023 )) / count ) / Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=( (21.583 + 19.045) / 2 ) / 8.856*365 / 4
=20.314 / 8.856*365 / 4
=209.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Protalix BioTherapeutics  (AMEX:PLX) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Protalix BioTherapeutics's Inventory Turnover for the three months ended in Dec. 2023 is calculated as

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Protalix BioTherapeutics's Inventory to Revenue for the three months ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.


Protalix BioTherapeutics Days Inventory Related Terms

Thank you for viewing the detailed overview of Protalix BioTherapeutics's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


Protalix BioTherapeutics (Protalix BioTherapeutics) Business Description

Traded in Other Exchanges
Address
2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement.
Executives
Dror Bashan director, officer: President and CEO 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 L3 20100
Eliot Forster director C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Aharon Schwartz director C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100
Zvi Shmuel Ben director 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 2161401
Dexcel Pharma Technologies Ltd. 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 3060000
Dan Oren 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 30600000
Eyal Rubin officer: Sr. VP and CFO C/O BRAINSTORM CELL THERAPEUTICS INC.,, 3 UNIVERSITY PLAZA DRIVE, STE 320, HACKENSACK NJ 07601
Yaron Naos officer: Sr. VP, Operations 2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL L3 20100
Yael Hayon officer: Vice President, R&D 2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL L3 2161401
Zeev Bronfeld director 6 URI STREET, TEL AVIV L3 64954
Amos Bar-shalev director C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 20100
David Granot director 6225 NEIL ROAD, RENO NV 89511
Pol F Boudes director C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Gwen A Melincoff director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Moshe Manor officer: President & CEO C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100